Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update
Gittus, Matt Haley, Helen Harris, Tess Borrows, Sarah Padmanabhan, Neal Gale, Danny Simms, Roslyn Williams, Terri Acquaye, Aaron Wong, Alisa
Gittus, Matt
Haley, Helen
Harris, Tess
Borrows, Sarah
Padmanabhan, Neal
Gale, Danny
Simms, Roslyn
Williams, Terri
Acquaye, Aaron
Wong, Alisa
Affiliation
University of Sheffield; Sheffield Teaching Hospitals NHS Trust; University Hospitals of North Midlands NHS Trust; PKD Charity; University Hospitals Birmingham NHS Foundation Trust; NHS Greater Glasgow and Clyde; Royal Free London NHS Foundation Trust; Hull and East Yorkshire Hospitals NHS Trust; Imperial College Healthcare NHS Trust; Guy's and St Thomas' NHS Foundation Trust
Other Contributors
Publication date
2025-02-14
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Autosomal Dominant Polycystic Kidney Disease (ADPKD) affects up to 70 000 people in the UK and the most common inherited cause of end-stage kidney disease (ESKD). It is generally a late-onset multisystem disorder characterised by bilateral kidney cysts, liver cysts and an increased risk of intracranial aneurysms. Approximately 50% of people with ADPKD reach ESKD by age 60. Disease-associated pain, discomfort, fatigue, emotional distress and, impaired mobility can impact health-related quality of life. The approval of tolvaptan, a vasopressin V2 receptor antagonist, has greatly advanced the care for people with ADPKD, shifting the focus from general chronic kidney disease management to targeted therapeutic approaches. While guidance from NICE and SMC provides a foundational framework, this is not clear or comprehensive enough to offer practical guidance for healthcare professionals in real-world settings. This commentary expands on the previous United Kingdom Kidney Association (UKKA) commentary in 2016 with an updated evidence base, the incorporation of real-world data and expert opinion to provide practical guidance to healthcare professionals. Through co-development with people affected by ADPKD, it now incorporates valuable patient perspectives and offers practical recommendations for the UK kidney community seeking to harmonise the quality of care of all people with ADPKD.
Citation
Gittus M, Haley H, Harris T, Borrows S, Padmanabhan N, Gale D, Simms R, Williams T, Acquaye A, Wong A, Chan M, Lee E, Ong AC. Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update. BMC Nephrol. 2025 Feb 14;26(1):79. doi: 10.1186/s12882-025-03960-4.
Type
Article